NEW YORK (GenomeWeb News) – The US Food and Drug Administration has revised the prescribing information for a class of epidermal growth factor receptor inhibitors for colorectal cancer to include information on variations in the KRAS gene that may affect patient response to the drugs.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genomic analysis of high-grade serous ovarian cancer, and more.

The new Riken president outlines some of his plans for the institute.

The Guardian discusses whether big science projects are worth the loss of resources available for other scientific pursuits.

An NEJM update from the ClinVar team highlights the difficulties of interpreting genetic variants.